Similarly, the combination of blinatumomab and nivolumab is being investigated in clinical trials to determine whether CTLA-4 inhibition with ipilimumab can further augment the immune response to eliminate CD19 positive B-ALL (NCT02879695). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.